Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Summary

The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).

Timeline

Start

2022-04-28

Primary completion

2022-07-07

Completion

2022-07-07

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision not related to safety concerns”

Drugs

Indications